NexImmune (NASDAQ:NEXI) Shares Down 3.9%

NexImmune, Inc. (NASDAQ:NEXI)’s stock price dropped 3.9% on Tuesday . The company traded as low as $5.29 and last traded at $5.36. Approximately 13,598 shares traded hands during trading, a decline of 99% from the average daily volume of 2,188,273 shares. The stock had previously closed at $5.58.

NexImmune Trading Down 3.9 %

The firm has a market capitalization of $5.68 million, a price-to-earnings ratio of -0.13 and a beta of 1.85. The stock’s 50 day moving average price is $7.51 and its two-hundred day moving average price is $5.46.

Institutional Investors Weigh In On NexImmune

Hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp boosted its position in shares of NexImmune by 9.6% in the first quarter. State Street Corp now owns 214,018 shares of the company’s stock worth $901,000 after acquiring an additional 18,730 shares during the last quarter. Raymond James & Associates acquired a new position in NexImmune during the first quarter valued at approximately $87,000. Renaissance Technologies LLC lifted its position in NexImmune by 44.7% during the first quarter. Renaissance Technologies LLC now owns 73,661 shares of the company’s stock valued at $310,000 after buying an additional 22,761 shares in the last quarter. Sei Investments Co. acquired a new position in NexImmune during the second quarter valued at approximately $43,000. Finally, Vanguard Group Inc. lifted its position in NexImmune by 6.1% during the third quarter. Vanguard Group Inc. now owns 473,977 shares of the company’s stock valued at $263,000 after buying an additional 27,057 shares in the last quarter. 9.85% of the stock is currently owned by hedge funds and other institutional investors.

NexImmune Company Profile

NexImmune, Inc, a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.